Mallinckrodt (MNK) Tops Q2 EPS by 20c; Boosts FY15 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. MSFT
3. GOOGL
4. EBAY
5. FTNT
6. TENB
7. KLAC
8. BIIB
9. CMG
10. ETSY

Go back to Mallinckrodt (MNK) Tops Q2 EPS by 20c; Boosts FY15 Outlook

Mallinckrodt plc Reports Fiscal 2015 Second Quarter Financial Results; Raises Full Year 2015 Guidance

May 5, 2015 6:55 AM EDT

DUBLIN, May 5, 2015 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty biopharmaceutical company, today reported results for the second quarter of fiscal 2015, which ended March 27, 2015.

Net sales were $909.9 million compared with $557.8 million in the second quarter of fiscal 2014, an increase of 63.1%. The increase was primarily driven by the inclusion and performance of H.P. Acthar® Gel (repository corticotropin injection) and OFIRMEV® (acetaminophen) injection, acquired in August 2014 and March... More